ArticleNature reviews. Clinical oncology2026

An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval.

Vivek Subbiah et al.PubMed ↗Publisher ↗

No numbers read from the abstract.